OIG identifies price variations in some drugs

Article Overview

This article covers an HHS Office of Inspector General review of drug pricing variation in physician practices and a Medicare response letter discussing the scope of the findings. It is relevant to coders, billing staff, compliance teams, and health care organizations that track drug-related reimbursement and payment policy issues. The article provides a high-level discussion of the report’s scope, the number of drugs reviewed and flagged, and the general context of repeated findings across multiple reports.